At the news
? BULLISHIMPACT 6/10 8-K filed Jun 18, 2026 at 08:01 ET
Denali Therapeutics (DNLI) announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The PRV was awarded following the March 2026 FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome. The $195M cash infusion is a non-dilutive capital event that strengthens Denali's balance sheet and provides funding to advance its broad clinical pipeline of TransportVehicle-enabled programs for lysosomal storage disorders and neurodegenerative diseases, including Sanfilippo syndrome, frontotemporal dementia, Pompe, and Alzheimer's. The transaction is subject to customary HSR closing conditions.
- Denali entered an asset purchase agreement to sell its Rare Pediatric Disease PRV for $195 million in cash on June 12, 2026
- PRV was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
- Proceeds will fund advancement of clinical pipeline including ETV, OTV, and ATV programs for multiple lysosomal storage disorders and neurodegenerative diseases
- Transaction subject to customary closing conditions including HSR antitrust waiting period expiration
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access